Anzeige
Mehr »
Donnerstag, 02.10.2025 - Börsentäglich über 12.000 News
Starkes Upside-Potenzial: Wachstumsstory mit starken Gehalten und großem Explorationspotenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40CZ4 | ISIN: SE0022239950 | Ticker-Symbol: 1YG0
Frankfurt
02.10.25 | 08:04
0,607 Euro
+3,76 % +0,022
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MENDUS AB Chart 1 Jahr
5-Tage-Chart
MENDUS AB 5-Tage-Chart

Aktuelle News zur MENDUS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12:34Mendus - New strategy to include CML alongside AML135Mendus has announced a strategy update, unveiling plans to expand the application of vididencel beyond the current lead programme in acute myeloid leukaemia (AML), to chronic myeloid leukaemia (CML)....
► Artikel lesen
08:00Mendus AB: Mendus announces updated clinical strategy and operational focus32Vididencel to be developed as a post-remission therapy across AML risk categories and in CML Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor...
► Artikel lesen
22.08.Mendus - Steady progress throughout Q225300Mendus's Q225 results reflect a period of progress across the pipeline. The lead programme, vididencel in acute myeloid leukaemia (AML), remains on track to be pivotal-stage ready in H225, creating...
► Artikel lesen
MENDUS Aktie jetzt für 0€ handeln
21.08.Mendus - Clinical activities on track285Mendus has reported its Q225 results. During the period, it made continued progress on the lead programme (vididencel in acute myeloid leukaemia, AML), which remains on track to be pivotal-stage ready...
► Artikel lesen
21.08.Mendus AB: Mendus AB Interim Report January - June 202594Expanding the vididencel opportunity In the second quarter of 2025, Mendus reported data from the pivotal Phase 2a ADVANCE II trial at different keynote conferences, confirming that its lead product...
► Artikel lesen
23.07.Mendus - Strengthened IP profile in ovarian cancer382Mendus has fortified its intellectual property (IP) profile for lead candidate, vididencel, with the granting of a new US patent covering its use in ovarian cancer (OC). While the lead programme for...
► Artikel lesen
23.07.Mendus AB: Mendus granted US patent for use of vididencel in ovarian cancer125Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence in life-threatening cancers, today announces that the United States Patent and...
► Artikel lesen
02.06.Mendus - Another encouraging ovarian cancer update316Mendus presented a positive clinical update for its Phase I ALISON trial in ovarian cancer at the 61st Annual American Society of Clinical Oncology conference (ASCO 2025). Importantly, the data demonstrated...
► Artikel lesen
07.05.Mendus - No surprises in Q125 update299Mendus's Q125 results came in as expected, with management confirming that vididencel (in acute myeloid leukaemia, AML) is on track to be pivotal-stage ready from H225. Recent highlights include regulatory...
► Artikel lesen
06.05.Mendus - Plans falling into place for vididencel pivotal study354Mendus's Q125 report included no surprises, with the company staying on track to secure large-scale GMP production of vididencel and Phase III readiness by H225, which we see as the most significant...
► Artikel lesen
06.05.Mendus AB: Mendus AB Interim Report January - March 2025134Phase 3 preparations and broader pipeline developments progress In the first quarter of 2025, Mendus provided a summary of the supportive feedback from EMA and FDA related to the preparations for a...
► Artikel lesen
05.05.Mendus AB: Mendus strengthens late-stage clinical development ability and appoints Dr Tariq Mughal as Chief Medical Officer289Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced the appointment of Tariq Mughal, MD FRCP FRCPath, as Chief Medical...
► Artikel lesen
04.04.Mendus (OMX: IMMU) presents DCOne platform update447On 3 April 2025, Mendus has announced that the company presented data from its proprietary DCOne platform at the Immunotherapy of Cancer Conference. The presentation showcased the potential of the platform...
► Artikel lesen
21.02.Mendus - CADENCE trial enrols first patient450Mendus has announced that the first patient has been enrolled in the CADENCE trial, sponsored by the Australasian Leukaemia and Lymphoma Group (ALLG). This is a multi-centre, randomised, controlled...
► Artikel lesen
21.02.Mendus (OMX: IMMU) notes first patient enrolment in the CADENCE trial399Mendus has announced that the first patient has been enrolled in the Phase II AMLM22-CADENCE trial, sponsored by the Australasian Leukaemia and Lymphoma Group. The trial is a multicentre, randomised...
► Artikel lesen
20.02.Mendus - Vididencel on track in AML going into 2025368Mendus has reported its FY24 results, reflecting an active period. Lead programme, vididencel in acute myeloid leukaemia (AML), had encouraging data from the ADVANCE II trial in December, laying the...
► Artikel lesen
13.02.Mendus - Focus firmly on pivotal-stage readiness in 2025420Mendus's FY24 results and subsequent management presentation highlighted its focus on advancing lead asset, vididencel, to pivotal-stage readiness. Backed by robust long-term monotherapy data from ADVANCE...
► Artikel lesen
13.02.Mendus AB: Mendus AB Year-end Report 2024175Preparations for pivotal-stage readiness of vididencel in AML on trackThe hard work of the Mendus team to advance the company's lead product vididencel in acute myeloid leukemia (AML) continued to pay...
► Artikel lesen
03.01.Mendus - Regulatory endorsement supports vididencel focus378Mendus's lead asset, vididencel, is fast approaching the pivotal stages of development in acute myeloid leukaemia (AML), with recent endorsements from both the FDA and EMA (on the design of the planned...
► Artikel lesen
02.01.Mendus AB: FDA and EMA feedback endorses vididencel registration trial preparations268Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, announces a summary of the feedback received from the US Food and Drug Administration...
► Artikel lesen
Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1